M&A Deal Summary |
|
|---|---|
| Date | 2024-12-30 |
| Target | Eli Lilly - Huminsulin |
| Sector | Medical Products |
| Buyer(s) | Lupin |
| Sellers(s) | Lilly |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1968 |
| Sector | Life Science |
| Employees | 24,006 |
| Revenue | 221.9B INR (2025) |
Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, Maharashtra.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 11 |
| Sector: Medical Products M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 3 of 3 |
| State: Indiana M&A | 1 of 1 |
| Country: United States M&A | 5 of 5 |
| Year: 2024 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-15 |
Lupin s U.S. Commercial Women s Health Specialty Business
Baltimore, Maryland, United States Lupin's U.S. Commercial Women's Health Specialty Business is focused on commercializing SOLOSEC (secnidazole) 2g oral granules. It is an FDA-approved single-dose antimicrobial agent that provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-04-02 |
Renascience Pharma
Luton, United Kingdom Renascience Pharma is a pharmaceutical company specialising in niche branded products for primary and secondary care. Renascience Pharma is based in Luton, United Kingdom. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 45.0B USD (2024) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. The company's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 10 |
| Sector: Medical Products M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 9 of 9 |
| State: Indiana M&A | 6 of 6 |
| Country: United States M&A | 10 of 10 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-08 |
Morphic
Waltham, Massachusetts, United States Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for treating serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. The company is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform that leverages Morphic's unique understanding of integrin structure and biology. Morphic is based in Waltham, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-02-25 |
Organovo - FXR program
San Diego, California, United States Organovo's FXR program focuses on developing treatments for inflammatory bowel disease. Organovo's FXR program is based in San Diego, California. |
Buy | - |
